fda warning letter hims compounded semaglutide september 2025 15, 2025: Telehealth company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines FDA Drug Recalls and Warnings:
Description
M., Alini, M., & Grad, S
Direct pricing at $149/month makes compounded semaglutide accessible regardless of insurance status
For example, a reduction in estrogen can lead to additional abdominal fat and muscle loss
The 22.5% average weight loss, with some patients achieving 25%+ reductions, offers the best chance of reaching a healthy weight range
In fact, individual characteristics significantly influence a patients likelihood of developing gallstones while on GLP-1 therapy
